{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:48:26Z","timestamp":1790153306019,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,15]],"date-time":"2011-10-15T00:00:00Z","timestamp":1318636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s11910-011-0236-5","type":"journal-article","created":{"date-parts":[[2011,10,14]],"date-time":"2011-10-14T12:15:15Z","timestamp":1318594515000},"page":"70-75","source":"Crossref","is-referenced-by-count":40,"title":["Enzyme Replacement Therapy for Pompe Disease"],"prefix":"10.1007","volume":"12","author":[{"given":"Corrado","family":"Angelini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Semplicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,15]]},"reference":[{"key":"236_CR1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0003-9861(73)90374-3","volume":"156","author":"C Angelini","year":"1973","unstructured":"Angelini C, Engel AG. Subcellular distribution of acid and neutral alpha-glucosidases in normal, acid maltase deficient, and myophosphorylase deficient human skeletal muscle. Arch Biochem Biophys. 1973;156:350\u20135.","journal-title":"Arch Biochem Biophys"},{"key":"236_CR2","first-page":"3389","volume-title":"The metabolic and molecular bases of inherited disease","author":"R Hirschhorn","year":"2001","unstructured":"Hirschhorn R, Reuser, AJ. Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency. In: CR Scriver BA, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389\u2013420","edition":"8"},{"key":"236_CR3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg van der","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372:1342\u201353.","journal-title":"Lancet"},{"key":"236_CR4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.0b013e31818da91e","volume":"71","author":"B Bembi","year":"2008","unstructured":"Bembi B, Cerini E, Danesino C, et al. Diagnosis of glycogenosis type II. Neurology. 2008;71:S4\u2013S11.","journal-title":"Neurology"},{"key":"236_CR5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.55.8.1122","volume":"55","author":"P Laforet","year":"2000","unstructured":"Laforet P, Nicolino M, Eymard PB, et al. Juvenile and adult onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 2000;55:1122\u20138.","journal-title":"Neurology"},{"key":"236_CR6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671\u20136.","journal-title":"J Pediatr"},{"key":"236_CR7","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"MLC Hagemans","year":"2005","unstructured":"Hagemans MLC, Winkel LP, Hop WC, et al. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64:2139\u2013214.","journal-title":"Neurology"},{"key":"236_CR8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/01.WNL.0000158682.85052.C0","volume":"64","author":"U Mellies","year":"2005","unstructured":"Mellies U, Stehling F, Dohna-Schwake C, et al. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology. 2005;64:1465\u20137.","journal-title":"Neurology"},{"key":"236_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","volume":"66","author":"ML Hagemans","year":"2006","unstructured":"Hagemans ML, Hop WJ, Van Doorn PA, et al. Course of disability and respiratory function in untreated lae onset Pompe disease. Neurology. 2006;66:581\u20133.","journal-title":"Neurology"},{"key":"236_CR10","unstructured":"Angelini C, Semplicini C, Ravaglia S, and the Italian GSDII Group. Long-term follow-up effects on enzyme replacement treatment of adult form of acid maltase deficiency myopathy. Acta Myologica. 2011; in Press."},{"key":"236_CR11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","volume":"63","author":"MLC Hagemans","year":"2004","unstructured":"Hagemans MLC, Janssens ACJW, Winkel LPF, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology. 2004;63:1688\u201392.","journal-title":"Neurology"},{"key":"236_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","volume":"6","author":"D Gungor","year":"2011","unstructured":"Gungor D, de Vries JM, Hop WCJ, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34.","journal-title":"Orphanet J Rare Dis"},{"key":"236_CR13","doi-asserted-by":"crossref","unstructured":"Kanters TA, Hagemans ML, van der Beek NA, et al. Burden of illness of Pompe disease in patients only receiving supportive care. Inherit Metab Dis. 2011 Apr 16. [Epub ahead of print].","DOI":"10.1007\/s10545-011-9320-x"},{"key":"236_CR14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/01.wnl.0000299892.81127.8e","volume":"70","author":"AC Nascimbeni","year":"2008","unstructured":"Nascimbeni AC, Fanin M, Tasca E, Angelini C. Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency. Neurology. 2008;70:617\u201326.","journal-title":"Neurology"},{"key":"236_CR15","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1083\/jcb.35.1.C1","volume":"35","author":"G Hug","year":"1967","unstructured":"Hug G, Schubert WK. Lysosomes in type II glycogenosis. Changes during administration of extract from Aspergillus niger. J Cell Biol. 1967;35:C1\u20136.","journal-title":"J Cell Biol"},{"key":"236_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","volume":"61","author":"S Kornfeld","year":"1992","unstructured":"Kornfeld S. Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors. Annu Rev Biochem. 1992;61:307\u201330.","journal-title":"Annu Rev Biochem"},{"key":"236_CR17","volume-title":"Fabry disease: perspectives from 5\u00a0Years of FOS","author":"EF Neufeld","year":"2006","unstructured":"Neufeld EF. Enzyme replacement therapy \u2013 a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5\u00a0Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 10."},{"key":"236_CR18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0883073807302598","volume":"22","author":"M Rossi","year":"2007","unstructured":"Rossi M, Parenti G, Della Casa R, et al. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells. J Child Neurol. 2007;22:565\u201373.","journal-title":"J Child Neurol"},{"key":"236_CR19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","volume":"356","author":"H Hout Van den","year":"2000","unstructured":"Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356:397\u20138.","journal-title":"Lancet"},{"key":"236_CR20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99\u2013109.","journal-title":"Neurology"},{"key":"236_CR21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","volume":"149","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Nicolino M, Voit T, et al. Results from a phase II trial of Chinese hamster ovary cell-derived recombinant human acid a-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149:89\u201397.","journal-title":"J Pediatr"},{"issue":"12","key":"236_CR22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.nmd.2010.09.011","volume":"20","author":"AT Ploeg van der","year":"2010","unstructured":"van der Ploeg AT. Where do we stand in enzyme replacement therapy in Pompe\u2019s disease? Neuromuscul Disord. 2010;20(12):773\u20134.","journal-title":"Neuromuscul Disord"},{"key":"236_CR23","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.0b013e31818da93f","volume":"71","author":"B Bembi","year":"2008","unstructured":"\u2022 Bembi B, Cerini E, Danesino C, et al. Management and treatment of glycogenosis type II. Neurology. 2008;71:S12\u201336. A task force of physicians reviewed the literature to provide guidelines for clinical and instrumental follow-up of GSDII patients, to monitor the natural course of the disease and to prevent and\/or treat early any complication of this multisystemic disorder.","journal-title":"Neurology"},{"issue":"15","key":"236_CR24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Ploeg van der","year":"2010","unstructured":"\u2022\u2022 van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362(15):1396\u2013406. This is the only double-blind randomized placebo-controlled study on efficacy of ERT in late onset patients. It demonstrated the efficacy of treatment in ameliorating motor and respiratory function.","journal-title":"N Engl J Med"},{"key":"236_CR25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigi-Pill N, Grunert B, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257:91\u20137.","journal-title":"J Neurol"},{"key":"236_CR26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","volume":"33","author":"B Bembi","year":"2010","unstructured":"Bembi B, Pisa FE, Confalonieri M, et al. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis. 2010;33:727\u201335.","journal-title":"J Inherit Metab Dis"},{"key":"236_CR27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","volume":"18","author":"CI Capelle van","year":"2008","unstructured":"van Capelle CI, Winkel LP, Hagemans ML, et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord. 2008;18:447\u201352.","journal-title":"Neuromuscul Disord"},{"key":"236_CR28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymgme.2010.01.015","volume":"100","author":"H Kobayashi","year":"2010","unstructured":"Kobayashi H, Shimada Y, Ikegami M, et al. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol Genet Metab. 2010;100:14\u20139.","journal-title":"Mol Genet Metab"},{"key":"236_CR29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ymgme.2010.04.005","volume":"100","author":"S Ravaglia","year":"2010","unstructured":"Ravaglia S, Carlucci A, Danesino C. Prognostic factors for late-onset Pompe disease with enzyme replacement therapy: the two sides of low BMI. Mol Genet Metab. 2010;100:388.","journal-title":"Mol Genet Metab"},{"key":"236_CR30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.nmd.2011.04.001","volume":"21","author":"D Orlikowski","year":"2011","unstructured":"Orlikowski D, Pellegrini N, Prigent H, et al. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord. 2011;21:477\u201382.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"236_CR31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/mus.20896","volume":"37","author":"MR Drost","year":"2008","unstructured":"Drost MR, Schaart G, van Dijk P, et al. Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve. 2008;37(2):251\u20135.","journal-title":"Muscle Nerve"},{"key":"236_CR32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jbiomech.2004.05.040","volume":"38","author":"MR Drost","year":"2005","unstructured":"Drost MR, Hesselink RP, Oomens CW, van der Vusse GJ. Effects of non contractile inclusions on mechanical performance of skeletal muscle. J Biomech. 2005;38:1035\u201343.","journal-title":"J Biomech"},{"key":"236_CR33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","volume":"3","author":"N Raben","year":"2007","unstructured":"\u2022 Raben N, Takikita S, Pittis MG, et al. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand.. Autophagy. 2007;3:546\u201352. This paper reviews the importance of autophagy in pathophysiology of GSDII and reveals new mechanisms involved in the disease.","journal-title":"Autophagy"},{"key":"236_CR34","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 2006;86:1208\u201320.","journal-title":"Lab Invest"},{"key":"236_CR35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","volume":"101","author":"N Raben","year":"2010","unstructured":"Raben N, Ralston E, Chien YH, et al. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab. 2010;101:324\u201331.","journal-title":"Mol Genet Metab"},{"key":"236_CR36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","volume":"6","author":"N Raben","year":"2010","unstructured":"Raben N, Schreiner C, Baum R, et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder\u2013murine Pompe disease. Autophagy. 2010;6:1078\u201389.","journal-title":"Autophagy"},{"key":"236_CR37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/auto.2984","volume":"2","author":"T Fukuda","year":"2006","unstructured":"Fukuda T, Roberts A, Ahearn M, et al. Autophagy and lysosomes in Pompe disease. Autophagy. 2006;2:318\u201320.","journal-title":"Autophagy."},{"key":"236_CR38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/ejhg.2010.188","volume":"19","author":"S Zampieri","year":"2011","unstructured":"Zampieri S, Buratti E, Dominissini S, et al. Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients\u2019 phenotypes. Eur J Hum Genet. 2011;19:422\u201331.","journal-title":"Eur J Hum Genet"},{"key":"236_CR39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/bj2720493","volume":"272","author":"LH Hoefsloot","year":"1990","unstructured":"Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J. 1990;272:493\u20137.","journal-title":"Biochem J"},{"key":"236_CR40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26\u201333.","journal-title":"Mol Genet Metab"},{"key":"236_CR41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","volume":"101","author":"JM Vries de","year":"2010","unstructured":"de Vries JM, van der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101:338\u201345.","journal-title":"Mol Genet Metab"},{"key":"236_CR42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease. Genet Med. 2011;13:729\u201336.","journal-title":"Genet Med"},{"key":"236_CR43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","volume":"152","author":"A Joseph","year":"2008","unstructured":"Joseph A, Munroe K, Housman M, et al. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol. 2008;152:138\u201346.","journal-title":"Clin Exp Immunol"},{"key":"236_CR44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","volume":"360","author":"NJ Mendelsohn","year":"2009","unstructured":"Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease. N Engl J Med. 2009;360:194\u20135.","journal-title":"N Engl J Med"},{"issue":"6","key":"236_CR45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/156652309790031094","volume":"9","author":"DD Koeberl","year":"2009","unstructured":"Koeberl DD, Kishnani PS. Immunomodulatory gene therapy in lysosomal storage disorders. Curr Gene Ther. 2009;9(6):503\u201310.","journal-title":"Curr Gene Ther."},{"issue":"5","key":"236_CR46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1139\/H09-093","volume":"34","author":"JP Little","year":"2009","unstructured":"Little JP, Phillips SM. Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab. 2009;34(5):817\u201328.","journal-title":"Appl Physiol Nutr Metab"},{"key":"236_CR47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mus.20665","volume":"35","author":"AE Slonim","year":"2007","unstructured":"Slonim AE, Bulone L, Goldberg T, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2007;35:70\u20137.","journal-title":"Muscle Nerve"},{"key":"236_CR48","doi-asserted-by":"crossref","unstructured":"Terzis G, Dimopoulos F, Papadimas GK, et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011 May 19. [Epub ahead of print].","DOI":"10.1016\/j.clinthera.2011.05.080"},{"key":"236_CR49","doi-asserted-by":"crossref","unstructured":"Levenson D. Late onset Pompe disease revealed by newborn screening. Am J Med Genet A. 2011;155A(5).","DOI":"10.1002\/ajmg.a.34061"},{"key":"236_CR50","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jpeds.2010.11.053","volume":"158","author":"YH Chien","year":"2011","unstructured":"\u2022 Chien YH, Lee NC, Huang HJ, et al. Later-onset pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr. 2011;158:1023\u20137. This paper discusses the importance of early diagnosis with newborn screening in metabolic myopathies such as GSDII, which may change more significantly the natural course of the disease.","journal-title":"J Pediatr"},{"key":"236_CR51","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","volume":"17","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther. 2009;17:954\u201363.","journal-title":"Mol Ther"},{"key":"236_CR52","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","volume":"30","author":"JJ Flanagan","year":"2009","unstructured":"Flanagan JJ, Rossi B, Tang K, et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat. 2009;30:1683\u201392.","journal-title":"Hum Mutat"},{"key":"236_CR53","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","volume":"1","author":"G Parenti","year":"2009","unstructured":"Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med. 2009;1:268\u201379.","journal-title":"EMBO Mol Med"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-011-0236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-011-0236-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-011-0236-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T14:38:07Z","timestamp":1560782287000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-011-0236-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,15]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1007\/s11910-011-0236-5","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,15]]}}}